Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
02/2009
02/25/2009CN100464566C Method and equipment of changed digital color image
02/25/2009CN100463916C Preparation of hemsleyadine-A and its use of preparing pharmaceutics against cancers
02/25/2009CN100463908C Substituted 8' -pyridinyl-dihydrospiro- [cycloalkyl] -pyrimido [1,2-a] pyrimidin-6-one and 8' -pyrimidinyl-dihydrospiro- [cycloalky]l -pyrimido p1,2-a] pyrimidin-6-one derivatives
02/25/2009CN100463906C Extraction method for daphnoretin
02/25/2009CN100463694C Virus coat protein/receptor chimeras and methods of use
02/25/2009CN100463688C Ointment with aloe and other five medicinal herbs and its preparation method
02/25/2009CN100463681C Artificial tears for treating xerophthalmia
02/25/2009CN100463680C Composition comprising soluble glucan oligomer from saccharomyces cerevisiae IS2 inhibiting the swine influenza (SIV) and transmissible gastroenteritis coronavirus (TGEV)
02/25/2009CN100463679C Clarithromycin soft capsule and its preparation
02/25/2009CN100463678C Ifosfamide compositions for parenteral administration and a process for their preparation
02/25/2009CN100463677C Preparation of nedaplatin freeze-dried powder injection
02/25/2009CN100463676C Control releasing venlafaxine hydrochloride tablet and its preparation
02/25/2009CN100463675C Soluble slow release external applied contraceptive
02/25/2009CN100463674C Oral cavity quick dissolved film containing civeran and method for preparing the same
02/25/2009CN100463673C Compound medicine release controlling film of chitosan, sodium alginate and gelatin and its preparing process
02/25/2009CN100463670C Microemulsion concentrate for oral administration of water-insoluble anti-cold drug and method for preparing same
02/25/2009CN100463669C Self-emulsifying agent of compound artemether
02/25/2009CN100463666C Composition for external use on skin
02/24/2009US7495127 Calcium-activated potassium channel (BK channel) with opening activity equivalent to or higher than that of maxikdiol, and has high specificity; pimaric acid, dihydropimaric acid, dihydroisopimarinol, sandaracopimaric acid, isopimaric acid, and dihydroisopimaric acid
02/24/2009US7495114 Cytotoxic agents containing novel potent taxanes and their therapeutic use
02/24/2009US7495111 Compounds useful as serotonin inhibitors and 5-HT1A agonists and antagonists
02/24/2009US7495110 Benzimidazole derivatives and their use as GnRH antagonists
02/24/2009US7495109 Nociceptin analogs
02/24/2009US7495108 Imidazoline derivatives having CB1-antagonistic activity
02/24/2009US7495107 Method for manufacturing isoxazole derivative or dihydroisoxazole derivative
02/24/2009US7495105 dissolving in solvent, adding resolution agent and water, refluxing, cooling, stirring, then filtering; anesthetics; cardiovascular disorders
02/24/2009US7495104 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors
02/24/2009US7495103 including cystic fibrosis transmembrane conductance regulator ("CFTR"), used for treating genetic disorders; respiratory system disorders
02/24/2009US7495099 Polyethylene glycol-polyglutamic acid block copolymer conjugates with e.g. 7-ethyl-10-hydroxycamptothecin or topotecan for sustained release; water solubility, anticancer agents
02/24/2009US7495088 Nuclease resistant nucleotide capable of hybridizing with complementary RNA in a manner which inhibits function of the RNA
02/24/2009US7495086 TWEAK receptor
02/24/2009US7495030 (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
02/24/2009US7495029 (2R) 2-propyloctanoic acid esterified, amidated, or salified with a moiety which when released modulates biochemical events during a stroke, such as a cyclooxygenase-2 (COX-2) inhibitor
02/24/2009US7495028 R-bambuterol, its preparation and therapeutic uses
02/24/2009US7495027 drugs that inhibit biosynthesis of bacterial cell walls, such as (5Z)-5-[(3',5'-dichloro-1,1'-biphenyl-3-yl)methylene]-3-(3,5-dichlorophenyl)-4-hydroxyfuran-2(5H)-one, used for treatment of bacterial infections, and as parasiticides
02/24/2009US7495026 Neo-tanshinlactone and analogs as potent and selective anti-breast cancer agents
02/24/2009US7495025 Antimalarial agents; multidrug-resistant malaria; e.g. [3-(1-Phenyl-vinyl)-1,2,5-trioxa-spiro[5.5]undec-9-ylidene]-acetic acid ethyl ester
02/24/2009US7495024 Use of e.g. N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl-2-propynyl]-N-hydroxyurea (ABT-761, Atreleuton)
02/24/2009US7495023 treat protozoan infections such as trypanosomiasis, malaria and leishmaniasis; also inhibiting cathepsins B and L to treat cancer; e.g. 3'-Bromopropiophenone Thiosemicarbazone
02/24/2009US7495022 α,β-unsaturated hydroxamic acid derivatives and their use as histone deacetylase inhibitors
02/24/2009US7495021 Benzothiazole- and benzooxazole-4,7-dione, derivatives and their use as cdc25 phosphate inhibitors
02/24/2009US7495020 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders
02/24/2009US7495019 Benzoisoselenazole derivatives with anti-inflammation, antivirus and antithrombosis activity and their use
02/24/2009US7495018 An enzyme inhibitor of p38 MAP kinase, an antagonist of tumor necrosis factors or adenosine receptor, a thiazole with the 5-pyridyl group derivatives
02/24/2009US7495017 3-(3-Cyclopentyloxy-4-methoxyphenyl)-1H-pyrazole;adenosine monophosphate activator; antiinflammatory agent, antidepressant, antiallergen, cognition activator, neurodegenerative diseases; arthritis, Alzheimer's disease, schizophrenia, Parkinson disease
02/24/2009US7495016 inhibiting HIV replication in a cell; inhibiting reverse transcriptase
02/24/2009US7495015 Inhibitors of p38 Mitogen-activated protein kinases (MAP kinases); arthritis, Crohns disease, irritable bowel syndrome, adult respiratory distress syndrome, chronic obstructive pulmonary disease, Alzheimer's disease; 6-(2-Fluoro-phenoxy)-3-phenyl-1H-indazole for example
02/24/2009US7495014 Gyrase inhibitors and uses thereof
02/24/2009US7495013 Chemokine receptor modulators or Histamine H1 antagonists; autoimmune, inflammatory, proliferative or hyperproliferative diseases, or immune diseases; Methyl 4-[[4-(2,4dichloro-3-methylphenoxy)-1-piperidinyl]methyl]-alpha-(phenylmethyl)-1-piperidineacetate for example
02/24/2009US7495012 Arylsulfonamides and uses related thereto
02/24/2009US7495011 Anti-coronavirus drug
02/24/2009US7495010 Muscarinic acetylcholine receptor antagonists
02/24/2009US7495009 Imidazopyridine derivatives as melancortin receptor agonists
02/24/2009US7495008 Spiro-piperidine derivatives
02/24/2009US7495007 Spiroindolinone derivatives
02/24/2009US7495006 reverse transcriptase (polymerase) inhibitor; viricide, antiproliferative agent; Retroviridae (including HIV), Hepadnaviridae (including HBV), or Flaviviridae (including BVDV and HCV) infection, AIDS
02/24/2009US7495005 Antidiabetic agents; antiarthritic agents; obesity; graft verses host disease; osteoporosis
02/24/2009US7495004 Purine derivatives as liver X receptor agonists
02/24/2009US7495003 e.g. 1-(naphthyl-1-ylmethyl)-3-(methoxycarbonylmethyl)-7-(but-2-ynyl)-8-(3-amino-piperidin-1-yl)-xanthine; dipeptidyl-peptidase-IV (DPP-IV) inhibitor; antidiabetic, diuretic, antihypertensive agent; insulin resistance, obesity; irritable bowel syndrome (IBS), Crohn's disease, ulcerative colitis
02/24/2009US7495002 e.g. 1-[(3-methyl-isoquinolin- 1 -yl)methyl]-3-methyl-7-(2-butyn- 1 -yl)-8-[(2-amino-ethyl) -methylamino]-xanthine; dipeptidyl-peptidase-IV (DPP-IV) inhibitor; antidiabetic, diuretic, antihypertensive agent; insulin resistance, obesity; irritable bowel syndrome (IBS), Crohn's disease, ulcerative colitis
02/24/2009US7495001 Benzannelated derivatives, their manufacture and use as pharmaceutical agents
02/24/2009US7495000 Variolin derivatives and their use as antitumor agents
02/24/2009US7494999 Sulfonyl-substituted bicyclic compounds as modulators of PPAR
02/24/2009US7494998 Benzisoxazole piperazine compounds and methods of use thereof
02/24/2009US7494997 excellent BCR-ABL tyrosine kinase inhibitory activity; to treat leukemias; 3-bromo-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino]phenyl}benzamide; compounds with cell growth inhibitory effect
02/24/2009US7494995 Phenylpyridylpiperazine compounds
02/24/2009US7494994 Phenylpyridylpiperazine compounds
02/24/2009US7494993 Enhanced activity, decreased toxicity, better solubility and improved pharmacokinetic profile; for inflammatory, immunological, CNS disorders, oncological disorders, bone diseases; Cyclohexanecarboxylic acid (4-chloro-3-{7-amino-1-methyl-2-oxo-1,4-dihydro-2H-pyrimido[4,5-d]pyrimidin-3-yl}-phenyl)-amide
02/24/2009US7494992 Antiparasitic terpene alkaloids
02/24/2009US7494991 For microbial infections specially Gram-positive bacterial infection; atherosclerosis-associated disease
02/24/2009US7494990 2-(piperidin-4-yl)-4,5-dihydro-2H-pyridazin-3-one derivatives as PDE4 inhibitors
02/24/2009US7494989 Pyridine compounds useful as N-type calcium channel antagonists
02/24/2009US7494988 Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease
02/24/2009US7494987 compounds with potent antitussive actions, high safety and less adverse actions; methyl 4-({1-[2-(4-cyanophenyl)ethyl]-3-hydroxyazetidin-3-ylmethyl}methylamino)benzoate
02/24/2009US7494986 central nervous system disorders like Depression, anxiety, cognition enhancer, antiinflammatory agents; 4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-4-phenylazocane
02/24/2009US7494985 Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use
02/24/2009US7494984 Substituted imidazo[1,2-a]pyrimidines as HIV viral DNA integrase inhibitors
02/24/2009US7494983 di-tert-butyl 4-{[1-(3,3-dimethyl-2-oxobutyl)-6-methoxy-1-H-indazole-3-yl]carbonyl}benzylphosphate; potassium channel blocker; eye neuroprotectant; hypotensive agent; glaucoma, elevated intraoccular pressure in the eye
02/24/2009US7494982 Modified oligonucleotides for telomerase inhibition
02/24/2009US7494981 Inhibition of interaction of PSD93 and PSD95 with nNOS and NMDA receptors
02/24/2009US7494978 Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
02/24/2009US7494950 Implantable, specific aspect ratio (length/diameter) from about 50:1 to about 1000:1; flexural strength, flexural toughness, and/or screw pullout strength; calcium phosphate
02/24/2009US7494824 Interactive system for presenting and eliminating substances
02/24/2009US7494680 Fat or oil composition
02/24/2009US7494674 Nutraceutical with tart cherries and method of treatment therewith
02/24/2009US7494668 "auxiliary" granulate obtained by wet granulation of D-mannitol and maize starch gum in a high shear granulator, microcrystalline cellulose, a sweetener, a flavoring agent and a lubricant; pleasant taste and the absence of perceptible granules in the mouth
02/24/2009US7494666 Administering to a mammal a formualtion comprising cationic lipids/DNA complex, allowing the complex to associate with angiogenic endothelial cells of an angiogenic blood vessel for a time such that the complex enters the target cells
02/24/2009US7494660 HCV NS3-NS4A protease resistance mutants
02/24/2009US7494642 Fatty acid derivatives; tissue-targeted therapy; tomography; cardiovascular disorders; liver disorders; kits
02/24/2009US7494503 Method and apparatus for acne prevention
02/24/2009CA2471338C Use of deoxypeganine for treating clinical depression
02/24/2009CA2469813C Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
02/24/2009CA2468370C Chronic, bolus administration of d-threo methylphenidate
02/24/2009CA2462741C Dry liposomal pvp-iodine compositions
02/24/2009CA2444208C Pharmaceutically acceptable salts containing local anesthetic and anti-inflammatory activities and methods for preparing the same
02/24/2009CA2443543C Supplementation of equine feedstuffs
02/24/2009CA2432085C Indole derivatives and their use as 5-ht2b and 5-ht2c receptor ligands
02/24/2009CA2426221C New neurokinin antagonists, processes for preparing them and pharmaceutical compositions containing these compounds
02/24/2009CA2417361C New phenyl- and phenylalkyl-substituted ethanolamines and ethylenediamines
02/24/2009CA2416109C Solid dose nanoparticulate compositions